VivaTech International

CompanyUnited States

VivaTech International develops one asset, in phase 2 (StroMed in osteoarthritis). Mostly cell therapy; based in the United States.

Assets
1
Furthest
Phase 2
Trials
3
Signals
0

Pipeline

1

  • StroMed

    Stromal vascular fraction formulation combined with platelet-rich plasma for tissue regeneration.

    Phase 2Cell therapyosteoarthritis

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms1
  • Trials3
  • Similar companies6

Updated 7 Oct 2026 · 6 sources

Intelligence